Literature DB >> 8899800

Endogenous tumor necrosis factor inhibits the cytotoxicity of exogenous tumor necrosis factor and adriamycin in pancreatic carcinoma cells.

N Watanabe1, N Tsuji, Y Tsuji, H Sasaki, T Okamoto, S Akiyama, D Kobayashi, T Sato, N Yamauchi, Y Niitsu.   

Abstract

Pancreatic carcinoma is one of the most devastating neoplasms with regard to its resistance to conventional therapy. In a previous report, we found that endogenous tumor necrosis factor (enTNF) exerts an intracellular protective effect against exogenous TNF- and Adriamycin (ADM)-induced cytotoxicity by scavenging oxygen free radicals (OFR) with induced manganous superoxide dismutase (MnSOD). We also know that glutathione S-transferase pi (GST-pi) and glutathione (GSH) also scavenge OFR. It remains unclear to what extent enTNF and MnSOD induced by enTNF regulate the sensitivity to ADM and exogenous TNF among different carcinoma cells. In this study, we examined the relationship between ADM and exogenous TNF sensitivity and en-TNF expression and MnSOD activity in four pancreatic carcinoma lines. We determined whether ADM and exogenous TNF sensitivity could be predicted by measuring enTNF expression and MnSOD activity in the carcinoma cells. The sensitivity to TNF and ADM varied with the cell lines, and TNF sensitivity correlated well with Adriamycin sensitivity. Moreover, enTNF expression and Mn-SOD activity correlated positively with resistance to ADM and exogenous TNF. When MIAPaCa-2 cells, which had the lowest enTNF expression and the highest sensitivity to exogenous TNF and ADM, were transfected with the nonsecretory-type human TNF gene (pTNF delta pro) to increase enTNF synthesis, their intracellular MnSOD activity and exogenous TNF and ADM resistance were increased. These findings suggest that MnSOD plays a critical role in scavenging OFR induced by ADM and exogenous TNF. enTNF is the most important factor that regulates the production of MnSOD. Therefore, it is plausible that inhibition of enTNF expression or MnSOD activity in pancreatic carcinoma would improve the efficacy of therapies for pancreatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899800     DOI: 10.1097/00006676-199611000-00009

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.

Authors:  Irene Esposito; Hany Kayed; Shereen Keleg; Thomas Giese; E Helene Sage; Peter Schirmacher; Helmut Friess; Jörg Kleeff
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

2.  Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.

Authors:  Mitsunobu R Kano; Younsoo Bae; Caname Iwata; Yasuyuki Morishita; Masakazu Yashiro; Masako Oka; Tomoko Fujii; Akiyoshi Komuro; Kunihiko Kiyono; Michio Kaminishi; Kosei Hirakawa; Yasuyoshi Ouchi; Nobuhiro Nishiyama; Kazunori Kataoka; Kohei Miyazono
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-16       Impact factor: 12.779

3.  Telomerase reverse transcriptase and telomeric-repeat binding factor protein 1 as regulators of telomerase activity in pancreatic cancer cells.

Authors:  T Yajima; A Yagihashi; H Kameshima; D Kobayashi; K Hirata; N Watanabe
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

4.  Augmented adriamycin sensitivity in cells transduced with an antisense tumor necrosis factor gene is mediated by caspase-3 downstream from reactive oxygen species.

Authors:  M Sasaki; D Kobayashi; N Watanabe
Journal:  Jpn J Cancer Res       Date:  2001-09

5.  Survivin as a radioresistance factor in pancreatic cancer.

Authors:  K Asanuma; R Moriai; T Yajima; A Yagihashi; M Yamada; D Kobayashi; N Watanabe
Journal:  Jpn J Cancer Res       Date:  2000-11

6.  Digitoflavone inhibits IκBα kinase and enhances apoptosis induced by TNFα through downregulation of expression of nuclear factor κB-regulated gene products in human pancreatic cancer cells.

Authors:  Xueting Cai; Wuguang Lu; Yang Yang; Jie Yang; Juan Ye; Zhenhua Gu; Chunping Hu; Xiaoning Wang; Peng Cao
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.